CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $544,896 | -64.0% | 19,800 | -52.9% | 0.01% | -58.1% |
| Q1 2023 | $1,513,894 | +8.6% | 42,076 | +34.5% | 0.03% | -3.1% |
| Q4 2022 | $1,393,838 | +33.6% | 31,273 | -15.7% | 0.03% | +23.1% |
| Q3 2022 | $1,043,000 | -82.9% | 37,118 | -83.6% | 0.03% | -83.8% |
| Q2 2022 | $6,086,000 | +7.6% | 225,765 | +35.9% | 0.16% | +22.1% |
| Q1 2022 | $5,657,000 | -4.3% | 166,065 | +8.6% | 0.13% | -5.8% |
| Q4 2021 | $5,910,000 | -30.9% | 152,950 | -3.4% | 0.14% | -41.1% |
| Q3 2021 | $8,547,000 | +112.6% | 158,309 | +31.7% | 0.24% | +82.9% |
| Q2 2021 | $4,021,000 | +163.2% | 120,238 | +62.0% | 0.13% | +126.3% |
| Q1 2021 | $1,528,000 | -51.5% | 74,199 | -58.7% | 0.06% | -51.3% |
| Q4 2020 | $3,148,000 | +14.1% | 179,670 | -3.5% | 0.12% | -29.9% |
| Q3 2020 | $2,760,000 | +1.7% | 186,117 | -10.9% | 0.17% | -10.2% |
| Q2 2020 | $2,715,000 | – | 208,836 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |